Drug Trial Radar · NCT04219046
Evaluation of Naloxegol in the Prevention of POI After Cystectomy
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2032
Primary completion
Jan 2032
Study completion Jan 2032
Sponsor
- Lead sponsor
- Institut Paoli-CalmettesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Postoperative ileus (POI) is defined as a transient reduction of bowel motility that prevents effective transit of bowel content and tolerance of oral intake following surgical interventions, especially after radical cystectomy. It remains a major factor associated with postoperative morbidity, length of hospital stay and medical costs. In order to optimize perioperative care for patients undergoing radical cystectomy in a context of an ERAS (Enhanced Recovery After Surgery) program, we will evaluate the effectiveness of systemic pharmacologic opioid antagonist treatment.
Conditions
- Bladder Cancer
- Cystostomy; Complications
Interventions
Naloxégol oxalateDrug
Oral administration once daily
Placebo oral tabletDrug
Oral administration once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time of hospital dischargeTime frame: Date at which treatment is initiated and date of hospital discharge (up to 12 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.